FDA has approved the first glucagon therapy that can be given without injection. Baqsimi, approved for patients aged 4 years and older, is the first approved glucagon therapy that can be given without an injection.
Approval was based on three studies — two adult studies (roughly 150 patients) and a pediatric study (roughly 50 patients) that compared a single dose of glucagon powder to a dose of injection.
Efficacy and safety outcomes were similar across studies.
Additionally, it shouldn't be given to patients with pancreatic or adrenal gland tissue tumors or sensitivities to the drug's ingredients.
Common side effects include headache, nasal congestion, nausea, upper respiratory tract irritation, vomiting, and watery eyes.
The list price for a single pack of Baqsimi is $280.80, according to the manufacturer.